This is an author produced version of a paper published in:
*Journal of Medical Economics*

Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa51093

**Paper:**
http://dx.doi.org/10.1080/13696998.2019.1645018

Released under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License (CC-BY-NC-ND).

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

http://www.swansea.ac.uk/library/researchsupport/ris-support/
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Stephen C. Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb & William J. Valentine

To cite this article: Stephen C. Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb & William J. Valentine (2019): Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK, Journal of Medical Economics, DOI: 10.1080/13696998.2019.1645018

To link to this article: https://doi.org/10.1080/13696998.2019.1645018

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

View supplementary material

Accepted author version posted online: 17 Jul 2019.
Published online: 02 Aug 2019.

Submit your article to this journal

Article views: 193

View Crossmark data
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Stephen C. Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb, and William J. Valentine

Introduction

With ~422 million people around the world living with the disease and incidence rates continuing to rise, diabetes mellitus represents one of the most serious challenges facing healthcare systems around the world. Type 2 diabetes in particular, which contributes 90% of all cases of diabetes mellitus, is the main driver of increasing prevalence with estimates suggesting that the number of people living with diabetes has doubled since 1980. Diabetes mellitus is a chronic, metabolic disease associated with significant morbidity and mortality, and characterized by elevated levels of blood glucose, which eventually leads to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes UK has estimated that ~4.7 million people in the UK have been diagnosed with diabetes mellitus, leading to the National Health Service (NHS) spending GBP 10 billion per year on the disease; around 10% of its overall budget. Moreover, evidence has indicated that ~80% of the total cost of diabetes mellitus is associated with the management of complications. However, several landmark studies have shown that maintaining good glycemic control can reduce the incidence of diabetes-related complications in the long-term, creating the potential to improve patient outcomes and reduce the burden of disease. Based on these data, the National Institute for Health and Clinical Excellence (NICE) recommends glycemic control targets for patients with type 2 diabetes. For those managed with lifestyle modifications and a single drug not associated with hypoglycemia, a glycated hemoglobin (HbA1c) target of 6.5% (48 mmol/mol) or below is recommended, and for those with diabetes not adequately controlled with monotherapy, a target of 7.0% (53 mmol/mol) or below is suggested. The guidelines further recommend that therapy should be intensified if HbA1c is greater than 7.5% (58 mmol/mol).

In 2017, Khunti and Millar-Jones published a literature review focused on therapeutic inertia in type 2 diabetes, or failure to intensify therapy despite poor glycemic control, in healthcare systems around the world. Type 2 diabetes in particular represents one of the most serious challenges facing diabetes mellitus, which contributes 90% of all cases of diabetes mellitus. The economic burden of poor glycemic control in type 2 diabetes in the UK is substantial. Efforts to avoid therapeutic inertia could substantially reduce diabetes-related complication costs even in the short-term.

Background and aims: Effective glycemic control is the cornerstone of successful type 2 diabetes management. However, many patients fail to reach glycemic control targets, and therapeutic inertia (failure to intensify therapy to address poor glycemic control in a timely manner) has been widely reported. The aim of the present study was to evaluate the economic burden associated with diabetes-related complications due to poor glycemic control for patients with type 2 diabetes in the UK.

Methods: A validated long-term model of type 2 diabetes (IQVIA CORE Diabetes Model) was used to project cost outcomes for a UK population with type 2 diabetes, based on data from The Health Improvement Network primary care database, at different levels of glycemic control. Costs associated with diabetes-related complications were accounted in 2017 Pounds Sterling (GBP). Complication costs were estimated for populations achieving different glycated hemoglobin (HbA1c) targets, in a number of delayed treatment intensification scenarios, and across a range of time horizons.

Results: For patients with an HbA1c level of 8.2% (66 mmol/mol), 7 years in poor control could increase mean costs associated with diabetes-related complications by over GBP 690 per patient and lead to costs of over GBP 1,500 in lost workplace productivity compared with achieving good glycemic control (HbA1c 7.0%, 53 mmol/mol) over a 10-year time horizon. Based on published estimates of the proportion of type 2 diabetes patients failing to meet glycemic targets in the UK, this corresponds to an additional economic burden of ~GBP 2,600 million (complication costs plus lost productivity costs).

Conclusions: The economic burden of poor glycemic control in type 2 diabetes in the UK is substantial. Efforts to avoid therapeutic inertia could substantially reduce diabetes-related complication costs even in the short-term.
the UK. The authors reported evidence that clinicians tend to have a reactive approach to therapy intensification, waiting for the worsening of hyperglycemia or complications to arise before intensifying treatment, and as a result patients will reach glycemic targets for only short periods, if at all. Median times to intensification with insulin therapy were ~6–7 years for patients on multiple oral antidiabetic drugs (OADs) and one study reported a median of 3.7 years [95% confidence interval = 3.4–4.0] for the intensification of insulin therapy from the time that high HbA1c levels (>7.5% [58 mmol/mol]) were recorded.

Recent evidence indicates that many patients with diabetes mellitus in the UK are not achieving the glycemic targets recommended by NICE. Data from the National Diabetes Audit has shown that one-third of people with type 2 diabetes in England and Wales had an HbA1c above 7.5% (58 mmol/mol) in 2016–2017. Similarly, estimates from Scotland have suggested that around 40% of people with type 2 diabetes have an HbA1c above 7.5% (58 mmol/mol). These figures suggest that there is an opportunity to bring a greater proportion of people with type 2 diabetes into good glycemic control and, in combination with addressing other modifiable risk factors through optimized therapy, reduce the costs associated with diabetes-related complications for healthcare payers and UK society as a whole.

The aim of the present study was to evaluate the economic burden associated with diabetes-related complications due to poor glycemic control for patients with type 2 diabetes in the UK.

Methods
Modeling approach
Long-term projections of clinical and cost outcomes were made using the IQVIA CORE Diabetes Model (version 9.0), a non-product specific diabetes policy analysis tool that has been validated against real-life data on original publication in 2004 and more recently in 2014. The architecture, assumptions, features, and capabilities of the model have been previously published. The model was used to evaluate complication rates, costs associated with diabetes-related complications, and costs arising from lost workplace productivity, including losses due to premature mortality. UK-specific life tables for 2015 from the World Health Organization were used for all analyses to capture background mortality, with remaining mortality due to diabetes-related complications also captured. The risk of cardiovascular complications was predicted using the UKPDS 68 equations. All simulations were performed using a first-order Monte Carlo approach.

Outcomes were projected over 3, 5, 10, 15, and 20 years, as well as patients’ lifetimes (Table 1). Scenarios evaluated outcomes with baseline HbA1c at 8.2% (66 mmol/mol), in line with the baseline value in the THIN population intensifying therapy, and 9.0% (75 mmol/mol), with target levels set to 6.5% (48 mmol/mol, in line with NICE guidance), 7.0% (53 mmol/mol), and 7.5% (58 mmol/mol) in separate analyses (Table 1). In line with published evidence from the UK, additional scenarios modeled intensifying patients immediately (within year 1) compared with a delay in intensification of 1, 3, 5, or 7 years (in line with Khunti and Millar Jones). In the modeling analysis, simulated patients were assumed to maintain good glycemic control (at a target HbA1c level), or to be in poor glycemic control (at the baseline HbA1c level) for a defined time period before HbA1c was lowered to the target level for the remainder of the time horizon (or the patient died in the simulation).

Cohort characteristics
Baseline patient characteristics were derived primarily from the population initiating therapy in the THIN primary care dataset in the UK, used by NICE in the health economic analysis supporting the development of guideline NG28 (published in December 2015). People with type 2 diabetes were selected from the THIN dataset using a combination of read codes for type 2 diabetes, and initial therapy baseline data were selected from people receiving their first single non-insulin anti-diabetes medication. Data were selected for the point at which people were first prescribed anti-diabetes medication other than insulin, with measurements recorded closest to the prescription date (<6 months). Patients were modeled with a baseline mean (standard deviation) age of 59.8 (12.6) years, mean duration of diabetes of 2.0 years, proportion male of 57.1%, proportion smokers of 19.1%, mean HbA1c of 8.2 (2.0)% (66 mmol/mol), mean systolic blood pressure of 139.6 (17.1) mmHg, mean total cholesterol of 4.96 (1.15) mmol/L, and mean body mass index (BMI) of 31.9 (3.2) kg/m² (see Supplementary Material for details). Missing values were supplemented with those from the trial population described by Pratley et al., as these values were not available from the THIN dataset and the trial population was comparable in terms of baseline demographics to the population initiating therapy in THIN, while mean number of cigarettes per day and alcohol consumption were based on UK-specific data for the general population. Where data could not be sourced from either THIN or Pratley et al. cohorts, characteristics were set to IQVIA CORE Diabetes Model default values. This cohort was assumed to be representative of patients in the UK early in the type 2 diabetes treatment continuum. Use of IQVIA CORE Diabetes Model...
default values in the modeling analysis was anticipated to have a modest impact on projected outcomes as these were derived from the UK Prospective Diabetes Study population, which was a newly-diagnosed UK type 2 diabetes cohort initiating therapy (in line with THIN population described above), and given that data for all key risk factors were taken from the THIN population (see Supplementary Table S1 for further details). Baseline HbA1c varied between 9.0% (75 mmol/mol) and 7.5% (58 mmol/mol) in scenario analyses.

Costs and other model settings

Costs associated with diabetes-related complications were derived from published sources and expressed in 2017 Pounds Sterling (GBP) (see Supplementary Material for details). No costs of glucose-lowering therapy were included in the analysis. Costs associated with lost workplace productivity were evaluated based on days off work estimates published by Sørensen and Ploug26 and country-specific estimates of mean salaries in simulated patients of working age (see Supplementary Material for details). Physiological parameter progression was assumed to remain constant over the duration of the analyses, to enable the comparison of different HbA1c targets and baseline levels. Future cost outcomes were discounted at 3.5% annually in line with published guidance, and undiscounted results are provided in the Supplementary Material.

Estimation of burden

A prevalence-based approach was used to estimate the country-level burden associated with poor glycemic control. Per patient differences in direct and indirect costs were multiplied by estimates of the number of patients in poor glycemic control based on the literature: 2,887,213 of the 3,208,014 patients with diabetes in the UK have type 2 diabetes;1,163,547 patients are in poor glycemic control based on the literature: 2,887,213 of the 3,208,014 patients with diabetes in the UK have type 2 diabetes (Tables 4 and 5). Stating that economic burden associated with poor glycemic control is substantial (Table 3). Total costs (mean complication and lost productivity costs) were over GBP 835 higher with 1 year in poor glycemic control over patients’ lifetimes, and notable increases in costs were already evident after only 3 years. A similar pattern of results was observed when poor control was defined as a mean HbA1c of 9.0% (75 mmol/mol) in the modeling analysis, with an even greater economic burden associated with poor glycemic control (Tables 4 and 5).

Results

Cost savings per patient

Long-term projections showed that 7 years in poor control could have a substantial impact on costs and clinical outcomes in patients with type 2 diabetes in the UK. For patients with an HbA1c level of 8.2% (66 mmol/mol), in line with data from the THIN primary care database, 7 years in poor control could increase mean direct costs by over GBP 690 and lead to mean costs of over GBP 1,500 in lost workplace productivity over a 10-year time horizon compared with achieving good glycemic control (HbA1c 7.0%, 53 mmol/mol) (Table 2). Over patients’ lifetimes, the economic burden was projected to be even higher, with 7 years in poor control adding over GBP 1,250 on average to direct medical costs and over GBP 1,600 in lost workplace productivity for each patient not achieving good glycemic control (HbA1c 7.0%, 53 mmol/mol). Estimation of the patient-level economic burden of just 1 year in poor glycemic control (HbA1c 8.2% [66 mmol/mol] vs 7.0% [53 mmol/mol]) showed that even with a short duration of poor glycemic control the economic impact was substantial (Table 3). Total costs (mean complication and lost productivity costs) were over GBP 835 higher with 1 year in poor glycemic control over patients’ lifetimes, and notable increases in costs were already evident after only 3 years. A similar pattern of results was observed when poor control was defined as a mean HbA1c of 9.0% (75 mmol/mol) in the modeling analysis, with an even greater economic burden associated with poor glycemic control.

Population level burden

Estimation of the economic burden at a population level, based on published estimates of patients with type 2 diabetes failing to meet glycemic control targets, indicated that 7 years in poor glycemic control (HbA1c 8.2%, 66 mmol/mol) increased the direct costs associated with diabetes-related

| Table 2. Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53 mmol/mol]) vs having poor glycemic control HbA1c 8.2% [66 mmol/mol] for 7 years. |
|---|---|---|
| Time horizon | 10 years | 15 years | Lifetime |
| Per patient outcomes |
| Savings due to complications avoided (GBP) | 691.58 | 1,003.93 | 1,256.53 |
| Savings due to lost productivity avoided (GBP) | 1,542.77 | 1,558.35 | 1,606.35 |
| Total cost savings (GBP) | 2,234.34 | 2,562.28 | 2,862.88 |
| Population outcomes |
| Savings due to complications avoided (GBP) | 805 million | 1,168 million | 1,462 million |
| Savings due to lost productivity avoided (GBP) | 1,795 million | 1,813 million | 1,869 million |
| Total cost savings (GBP) | 2,600 million | 2,981 million | 3,331 million |

Table shows discounted outcomes (3.5% per annum).

Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.
complications by ~GBP 805 million over a 10-year time horizon compared with good glycemic control (HbA1c 7.0%, 53 mmol/mol) (Table 2). Costs associated with lost productivity in this scenario were projected to be GBP 1,795 million, giving a total economic burden estimate of ~GBP 2,600 million for 7 years of poor glycemic control at a population level over a 10-year time horizon. Cardiovascular complications were the biggest driver of direct costs, accounting for half of all direct medical costs in the modeled scenarios (Figure 1). Over patients’ lifetimes, the total economic burden of 7 years in poor glycemic control was estimated to be GBP 3,331 million in this scenario.

A substantial economic burden was evident even at much shorter time horizons. Assuming poor glycemic control for 1 year (HbA1c 8.2%, 66 mmol/mol), the modeling analysis indicated the total additional costs (direct plus indirect costs) were ~GBP 571 million after only 3 years vs maintaining good glycemic control throughout (HbA1c 7.0%, 53 mmol/mol) (Table 3). This pattern of results was reflected when modeling poor glycemic control at an HbA1c level of 9.0% (75 mmol/mol), with more pronounced savings (Tables 4 and 5, Figure 2).

Discussion

Delays in achieving good glycemic control in patients with type 2 diabetes are likely to represent a huge economic burden in the UK. The modeling analysis presented in this paper was designed to evaluate the potential burden of time spent in poor glycemic control, as reported in publications describing therapeutic inertia. The analysis showed that even a short time (1 year) in poor glycemic control (HbA1c 8.2%, 66 mmol/mol) could cost an additional GBP 197 million for the management of diabetes-related complications over the

<table>
<thead>
<tr>
<th>Table 3.</th>
<th>Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53 mmol/mol]) vs having poor glycemic control HbA1c 8.2% [66 mmol/mol] for 1 year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time horizon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 years</td>
</tr>
<tr>
<td>Per patient outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>72.99</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>417.57</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>490.56</td>
</tr>
<tr>
<td>Population outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>85 million</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>486 million</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>571 million</td>
</tr>
</tbody>
</table>

Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.

<table>
<thead>
<tr>
<th>Table 4.</th>
<th>Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53 mmol/mol]) vs having poor glycemic control HbA1c 9.0% [75 mmol/mol], for 7 years.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time horizon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 years</td>
</tr>
<tr>
<td>Per patient outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>1,217.33</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>2,679.48</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>3,896.81</td>
</tr>
<tr>
<td>Population outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>1,416 million</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>3,118 million</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>4,534 million</td>
</tr>
</tbody>
</table>

Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.

<table>
<thead>
<tr>
<th>Table 5.</th>
<th>Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53 mmol/mol]) vs having poor glycemic control (HbA1c 9.0% [75 mmol/mol]) for 1 year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time horizon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 years</td>
</tr>
<tr>
<td>Per patient outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>126.51</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>786.91</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>915.42</td>
</tr>
<tr>
<td>Population outcomes</td>
<td></td>
</tr>
<tr>
<td>Savings due to complications avoided (GBP)</td>
<td>147 million</td>
</tr>
<tr>
<td>Savings due to lost productivity avoided (GBP)</td>
<td>918 million</td>
</tr>
<tr>
<td>Total cost savings (GBP)</td>
<td>1,065 million</td>
</tr>
</tbody>
</table>

Table shows discounted outcomes (3.3% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.

Figure 1. Mean cost of diabetes-related complications associated with 7 years in poor control (HbA1c 9.0% or 8.2%) vs effective glycemic control (HbA1c 7.0%) over a 10-year time horizon. Cardiovascular complications include myocardial infarction, angina, stroke, heart failure, and peripheral vascular disease. Renal complications include microalbuminuria, gross proteinuria, end-stage renal disease (dialysis), and renal transplant. Diabetic foot/neuropathy complications include foot ulcers, peripheral neuropathy, and amputation. Ocular complications refer to all eye disease (retinopathy, macular edema, cataract, and severe vision loss).

Figure 2. Mean cost of diabetes-related complications associated with 1 year in poor control (HbA1c 9.0% or 8.2%) vs effective glycemic control (HbA1c 7.0%) over a 10-year time horizon. Cardiovascular complications include myocardial infarction, angina, stroke, heart failure, and peripheral vascular disease. Renal complications include microalbuminuria, gross proteinuria, end-stage renal disease (dialysis), and renal transplant. Diabetic foot/neuropathy complications include foot ulcers, peripheral neuropathy, and amputation. Ocular complications refer to all eye disease (retinopathy, macular edema, cataract, and severe vision loss).
next 10 years. Factoring in lost workplace productivity, the total cost of 1 year in poor glycemic control could be as high as GBP 975 million over the next 10 years.

Whilst the present study is hypothetical in nature, much of the data modeled was aligned with evidence from the type 2 diabetes population in the UK. For example, cohort characteristics were taken primarily from THIN primary care database analysis used by NICE for the health economic analysis supporting the development of guideline NG28 and HbA1c targets were aligned with those recommended by NICE\textsuperscript{9,22}. It is noteworthy that the NICE HbA1c targets are different dependent on patient characteristics and therapies, and an individualized approach is recommended; therefore, we included multiple HbA1c targets in the present analysis. Assumptions around time in poor control were aligned with the data published by Khunti and Millar-Jones\textsuperscript{10} in 2017, indicating median times to intensification of 2.9 years from OAD monotherapy to OAD dual therapy (see Supplementary Material for 3-year delay results), 7.2 years from OAD dual to triple therapy, and 6.7 years from OAD triple therapy to insulin initiation. Complication costs were taken from published UK-specific sources (see Supplementary Material) and lost productivity costs were based on UK estimates of average salaries, working days, and retirement age, albeit with days-off-work estimates from a Danish study (as no UK-specific estimates were identified in literature review). The accumulation of lost workplace productivity costs in the modeling simulations was observed to be primarily in the first few years of the simulations, when the majority of patients were below retirement age and therefore incurring lost workplace productivity when complications occurred. With data suggesting the diagnosis of type 2 diabetes is becoming increasingly common in younger people, for example the National Diabetes Audit 2016–2017 report 6,836 aged under 25 years with the disease, the potential burden of lost workplace productivity associated with the condition is vast\textsuperscript{10,29}.

The estimates presented here are consistent with previous analyses in the UK setting. For example, Baxter et al\textsuperscript{20} reported that modest improvements in glycemic control could generate significant reductions in the incidence and, therefore, in the cost of complications in people with type 1 or type 2 diabetes based on a modeling analysis\textsuperscript{30}. By projecting outcomes for populations stratified by HbA1c, cost reductions in the UK adult type 2 diabetes population associated with treating patients to NICE HbA1c targets were estimated at GBP 299 million over 5 years, rising to GBP 4,506 million over 25 years. Hex et al\textsuperscript{53} had previously reported annual direct costs of diabetes-related complications of GBP 7,000 million in the type 2 diabetes population in 2010/2011, and projected it could rise to GBP 12,224 million in 2035/2036. Both of these studies provide evidence that improving glycemic control in the type 2 diabetes population could drive substantial reductions in the economic burden associated with the disease.

As with any modeling analysis, it is important to acknowledge the limitations of the present study to appropriately contextualize the findings. Modeling analyses that make long-term projections of outcomes are, by definition, associated with a degree of uncertainty. In the present analysis, a widely used, published, and validated health economic model of type 2 diabetes (IOVIA CORE Diabetes Model) was used to minimize this uncertainty\textsuperscript{17–19}. The analysis used assumptions on HbA1c progression (constant linear progression) to facilitate the comparison between different levels of glycemic control. Whilst this is almost certainly a simplification of reality (where HbA1c may vary considerably across the population), it was an important part of the analysis to allow clear interpretation of findings. Whilst the focus of the present analysis was on quantifying the burden associated with poor glycemic control, it is noteworthy that effective management of patients with type 2 diabetes involves addressing multiple risk factors, including reduction of excess body weight, smoking cessation, and improving blood pressure and serum lipid levels, amongst others\textsuperscript{21}. Therapeutic choices with the goal of achieving good glycemic control can also impact these additional risk factors, along with lifestyle factors and other medications. Targeting multiple risk factors, not just glycemic control, in the management of patients with type 2 diabetes has the potential to further reduce the economic burden associated with diabetes-related complications than the estimates reported in the present analysis. Another potential limitation of the analysis was in the estimation of lost workplace productivity. Limited data availability meant that separate estimates of mean salary could not be used for males and females or stratified by patient age. Given that the risk of several end stage complications is generally higher in males, this may lead to an under-estimation of the economic burden of diabetes-related complications. In addition, the impact of diabetes-related complications leading to enforced retirement from the workforce or of their avoidance leading to delayed retirement were not captured in the present analysis.

Hypoglycemia was not included in the study as the analysis was focused on evaluating the costs associated with diabetes-related complications and not the costs of interventions or their side-effects. That acknowledged, inclusion of hypoglycemia in the present study would have had little or no impact on the estimates of economic burden as the risk of severe hypoglycemia would be unlikely to change significantly over the HbA1c levels in the present analysis. Lipska et al\textsuperscript{32} reported comparable risk of severe hypoglycemia in patients with HbA1c between 6.0 and 6.9% (42 and 52 mmol/mmol), 7.0 and 7.9% (53 and 63 mmol/mmol), 8.0 and 8.9% (64 and 74 mmol/mmol) in an analysis of over 9,000 type 2 diabetes patients in the US. Hypoglycemia risk was only elevated in patients with low HbA1c levels (<6%, 42 mmol/mol) and high HbA1c levels (≥9%, 75 mmol/mol). Moreover, the risk of hypoglycemia can be mitigated by careful selection of medications that are associated with a lower risk of hypoglycemia than traditional agents such as sulfonylurea and human insulin\textsuperscript{33}. Estimates of population level burden were made using published prevalence data in line with previous studies\textsuperscript{30}. It is worth noting, however, that this is likely to underestimate the true burden of disease and it only quantifies clinical and cost outcomes for the prevalent cohort. Incident patients, for example those who are...
diagnosed with type 2 diabetes next year or the year after that, are not included in the prevalence-based estimates of burden, but incidence-based estimates of burden are provided as additional information in the Supplementary Material.

The present analysis did not include the costs of diabetes therapy, as the aim was to evaluate the cost of complications associated with poor glycemc control and providing an accurate estimate of treatment costs was not possible within the context of the analysis. It is noteworthy that additional healthcare spending on glucose-lowering therapy would be required for intensification and is, potentially, justified by the findings of this study. Providing an accurate estimate of therapy costs is challenging, given the wide array of therapeutic options currently available to manage patients with type 2 diabetes and the individual variation in optimizing patients’ therapy to make the HbA1c improvements described in the present analysis. Evaluating these costs, perhaps using a real-life cohort stratified by HbA1c level to compare the use of different therapies and associated costs, could represent an interesting future avenue of research. Similarly, the routine costs of management of diabetes patients were not included in the present study. Whilst these costs would be expected to be the same in patients in good glycemc control and those in poor control, the survival paradox (whereby patients who live longer cost more and are at risk of complications for a longer period) may mean that patients in good glycemc control accrue slightly higher routine management costs than their counterparts in poor glycemc control, although this would be expected to only have a very modest impact on the outcomes of the analysis.

Conclusions
It is well established that the clinical and economic burden of poor glycemc control in type 2 diabetes in the UK is substantial. The present modeling analysis indicates that efforts to avoid delaying treatment intensification could reduce the economic burden associated with diabetes-related complications. With published estimates suggesting that over 40% of patients with type 2 diabetes in the UK have an HbA1c level ≥7% (53 mmol/mol), there is a clear need to encourage earlier intensification and address issues around therapeutic inertia. Model projections indicate that the benefits of intensification would already be substantial at a population level after only 3 years, and would continue to accumulate over patients’ lifetimes.

Transparency
Declaration of funding
This work was funded by Novo Nordisk A/S.

Declaration of financial/other interests
SCB has received research grants (including principal investigator, collaborator or consultant) from Healthcare and Research Wales (Welsh Government) and Novo Nordisk; has received other research support and honoraria from Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Sanofi; and has ownership interest in Glycosmedia (diabetes on-line news service). BBH and BC are employees and shareholders of Novo Nordisk. JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions
WJV and BH were involved in the design of the study, modeling work and data analysis. WJV drafted the paper and BH reviewed critically for intellectual content. SB was involved in interpretation, reviewing and revising the paper critically for intellectual content. BBH and BC were involved in design of the study, interpretation and reviewed critically for intellectual content. BC, WJV, BH, BBH and BC all agreed to be accountable for all aspects of the work.

Acknowledgements
None reported.

ORCID
Barnaby Hunt http://orcid.org/0000-0001-5420-279X

References


